Chulijing tablet manufacturing is anchored by the relationship between API load and tablet compressibility. In production-scale direct compression, drug load is generally limited to 20% w/w to 35% w/w when the API median particle diameter (D50) exceeds 75 µm, because larger particles create segregation in bin blenders and increase tablet weight variability. A representative formulation for a 300 mg tablet delivering 60 mg Chulijing uses 20% w/w API, 30% w/w microcrystalline cellulose, 45% w/w lactose monohydrate, 2% w/w crospovidone, 0.5% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate; final hardness is maintained at 60–90 N on a Schleuniger hardness tester, while friability must remain below 0.8% according to Ph. Eur. 2.9.7. Compliance for veterinary tablet release includes Ph. Eur. monograph 0478 (Tablets), USP General Chapter <905> Uniformity of Dosage Units, USP General Chapter <711> Dissolution, and disintegration testing per Ph. Eur. 2.9.1 with purified water at 37±2°C. The downstream manufacturing process for wet granulation consists of high-shear preblending in a Diosna P 1/6 at impeller speed 200–400 rpm for 3–5 min, addition of purified water at 8–15% w/w, wet massing until amperage rises by 20–30%, fluid-bed drying at inlet air temperature 55–70°C to a loss-on-drying endpoint of 1.5–2.5%, calibration through a 0.8 mm screen, and final blending with lubricant for 3 min. Tablet compression is performed on a Korsch XL 400 rotary press at 40–60 rpm with precompression force 5–8 kN and main compression force 15–25 kN. Terminal finished products include immediate-release film-coated tablets for swine, calves, and companion animals; dispersible tablets for administration via feed or water; and divisible scored tablets for weight-adjusted dosing in small ruminants.

Why Do Capsule Blends Require Tighter API Particle Size Control Than Tablet Blends?

Capsule filling demands tighter control over bulk density and flow because dosator and tamping-pin machines fill by volume rather than weight. A Chulijing capsule formulation is typically prepared by dry granulation when the API proportion exceeds 35% w/w or when the API is cohesive; the dry granulate is produced on a Gerteis Mini-Pactor roller compactor with roll pressure 4–8 kN/cm, granulator mesh 0.8–1.2 mm, and screening to remove fines below 150 µm. The formulation addition ratio is derived from fill weight and label claim: a size 0 hard gelatin capsule with a fill weight of 400 mg delivering 50 mg Chulijing contains 12.5% w/w API; lower-dose capsules may use 5–10% w/w API with lactose monohydrate and pregelatinized starch as bulking excipients. Compliance for this dosage form includes Ph. Eur. monograph 0016 (Capsules), USP General Chapter <711> Dissolution using Apparatus 1 at 100 rpm in 900 mL of 0.1 M HCl, USP General Chapter <905> Uniformity of Dosage Units, and Ph. Eur. 2.9.5 for mass uniformity. On a Bosch GKF 1500 capsule filling machine, powder bridging in the hopper can increase weight variation above ±3% RSD; this is mitigated by maintaining excipient moisture below 2.0% and adding 0.25–0.5% w/w colloidal silicon dioxide before final blending. The finished product line includes hard gelatin capsules for companion animals, calves, and swine, packaged in HDPE bottles with induction-sealed caps and desiccant sachets when required by stability data. Published data for Chulijing-specific capsule dissolution limits under biorelevant veterinary media remain limited.

When Terminal Sterilization Is Not Feasible for Aqueous Veterinary Injections

Formulation of Chulijing as an aqueous injection requires pH and oxygen control because the API may undergo hydrolysis in aqueous media at extremes. The manufacturing process begins with dissolution in Water for Injection at a temperature of 25–40°C under nitrogen sparging in 316L stainless steel compounding tanks. The addition ratio is expressed as concentration: a 10% w/v solution contains 100 mg/mL Chulijing; lower-strength products at 5% w/v (50 mg/mL) are prepared for smaller species or extended dosing intervals. Formulation excipients include 0.1–0.5% w/v antioxidant such as sodium metabisulfite, 0.2–0.5% w/v tonicity-adjusting sodium chloride, and pH adjustment with 0.1 M HCl or 0.1 M NaOH to a target pH of 5.0–6.5. Compliance for injectable veterinary medicinal products includes USP General Chapter <1> Injections, USP General Chapter <71> Sterility, USP General Chapter <85> Bacterial Endotoxins with a limit not exceeding 0.5 EU/mg unless otherwise justified, Ph. Eur. general chapter 0520 Parenteral Preparations, and VICH GL18 for residual solvents. The solution is clarified through 0.45 µm and sterilizing 0.22 µm polyvinylidene fluoride membrane filters, then aseptically filled into amber glass vials under Grade A conditions within an isolator. If terminal sterilization is possible, a cycle at 121°C for 15 min is used only after confirming no degradation products above 0.5% peak area. Production-scale bottlenecks include filter clogging due to API polymorph conversion and stopper leachables; vial headspace oxygen is reduced to below 2% by nitrogen flushing. Terminal products include intramuscular or subcutaneous injections for cattle, swine, sheep, and companion animals, supplied in 10 mL, 50 mL, and 100 mL amber glass vials. Published data for Chulijing-specific terminal sterilization stability remains limited.

Dosage form	Primary standard	Secondary standard	Critical release parameter
Tablets	Ph. Eur. 0478	USP <905>	Friability ≤0.8%
Capsules	Ph. Eur. 0016	USP <711>	Dissolution Q ≥80% at 45 min
Injections	Ph. Eur. 0520	USP <71>	Endotoxin ≤0.5 EU/mg
Powders	EU GMP Part II	USP <795>	Blend uniformity RSD ≤5%
Premixes	EU 2019/4	FDA 21 CFR 225	Homogeneity CV ≤5%; carryover controls per Annex I
Solutions	Ph. Eur. 0672	Ph. Eur. 5.1.3	Preservative efficacy in aqueous vehicle

Water-soluble powder production for mass medication via drinking water differs from premix manufacturing in that the blend must dissolve rapidly in hard water with residual alkalinity and metal ions. The addition ratio in the powder concentrate is typically 10% w/w to 50% w/w Chulijing, depending on target drinking water inclusion rate; for example, a 100 g sachet containing 20 g active substance is added to 100–200 L of drinking water to achieve the labeled mg/L dose. Compliance is governed by the registration dossier under Regulation (EU) 2019/6 for veterinary medicinal products, and good manufacturing practice per EU GMP Part II with WHO Technical Report Series No. 957 Annex 2. The downstream process uses a horizontal ribbon blender with a working capacity of 500–1000 kg; the API is preblended with a portion of glucose monohydrate in a stepwise geometric dilution until a 1:10 preblend is achieved, then charged to the main blender and mixed for 15–20 min at 10–15 rpm. Blend uniformity is monitored by sampling 10 locations and requiring 90.0–110.0% label claim with RSD below 5.0%. Packaging is performed in low-humidity rooms with RH below 40%, using aluminum foil laminated sachets to limit moisture ingress. Production bottlenecks include caking when ambient humidity exceeds 55% and adhesion of fine API to stainless steel surfaces. Terminal products include 100 g, 500 g, and 1 kg water-soluble powder sachets for poultry, swine, and calves, as well as bulk containers for large farms.

Medicated Premix Homogeneity Limits in High-Fat Broiler Rations

Medicated premix manufacture addresses carryover and segregation because the target inclusion in final feed is small relative to the total ration mass. The addition ratio in the premix is usually 1% w/w to 20% w/w Chulijing; the premix is then diluted into final feed at 0.1–1.0 kg per tonne, yielding active concentrations in the mg/kg range. Compliance for medicated feed incorporates EU Regulation (EU) 2019/4 on the manufacture, marketing and use of medicated feed, including Annex I requirements for homogeneous dispersion and carryover limits; for export to the United States, the Type A medicated article framework under FDA 21 CFR 225 and current good manufacturing practice in 21 CFR 225.1 may apply. The manufacturing process uses a stepwise dilution sequence: API is first mixed with a compatible carrier such as calcium carbonate or rice hulls in a 1:10 ratio, then this intermediate is extended in a 500 kg ribbon blender to the final premix strength. The granulation step, when required, is conducted in a fluid-bed granulator with top-spray binder such as povidone K30 at 2–5% w/w, inlet air temperature 60–80°C, and final moisture below 4%. Granule particle size is controlled between 150 µm and 850 µm because larger granules segregate in high-fat rations and smaller fines increase dust losses. Bulk density of the granulated premix is maintained at 0.45–0.65 g/mL to match feed carrier flow in volumetric metering systems. Homogeneity is assessed by collecting 10 samples from different blender zones; the coefficient of variation should not exceed 5% for low-dose premixes. A production-scale bottleneck occurs when the premix is added to pelleted feed before conditioning; heat-labile Chulijing may degrade if conditioning exceeds 80°C for more than 30 s, so post-pelleting liquid application or lower-temperature extrusion is used. In high-fat broiler rations containing 4–7% added oil, dry premix adhesion to mixer walls and carryover into subsequent batches is reduced by selecting hydrophilic carriers and implementing flush batches according to EU 2019/4 Annex I. Terminal products include Type A medicated premixes, granulated premixes for feed mills, and direct-to-farm premixes in 5 kg, 10 kg, and 25 kg polyethylene-lined paper bags.

What Limits Stability of Aqueous Oral Solutions in Poultry Drinking Water?

Oral solutions of Chulijing are exposed to potable water of variable pH, hardness, and residual chlorine in poultry drinking lines, so formulation must buffer against chemical degradation and precipitation. The addition ratio is expressed as concentration of active substance in the liquid concentrate, commonly 2% w/v to 20% w/v; a 10% w/v solution contains 100 mg/mL Chulijing and is typically metered through a dosing pump at 1% into the drinking water line, resulting in a final concentration in the mg/L range. Compliance for oral liquid veterinary medicinal products includes Ph. Eur. monograph 0672 (Liquid preparations for oral use), Ph. Eur. general chapter 5.1.3 Antimicrobial effectiveness testing for preserved aqueous preparations, and USP General Chapter <795> when prepared as a compounded oral vehicle. The manufacturing process involves dissolving the API in purified water adjusted to pH 4.5–6.0 with citric acid/sodium citrate buffer at 0.05–0.2 M; preservatives such as methylparaben sodium 0.1–0.2% w/v and propylparaben sodium 0.01–0.05% w/v are added to prevent microbial growth. High-shear mixing at 500–1500 rpm for 10–20 min is followed by filtration through a 10 µm polypropylene filter. The product is filled into amber polyethylene terephthalate or glass bottles with dosing cups or calibrated droppers. A production bottleneck is the formation of insoluble complexes when the API encounters manganese and iron ions in hard water; chelating agents such as disodium edetate at 0.01–0.05% w/v are included to mitigate precipitation. Terminal products include oral drench solutions for calves, swine, and sheep; drinking water concentrates for poultry and swine; and calibrated-dosing bottles for companion animals. Published data for Chulijing-specific photo-oxidation kinetics in drinking water distribution systems remains limited.